N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

204 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To find possible therapeutic targets to help prevent long-term brain and behavioural side effects in survivors of childhood leukemia that may have been caused by chemotherapy (Treatment-Related late Adverse Neuro-Cognitive Effects: TRANCE). The study hypothesis is that genetic variations of the elements in the folate-related cycles and methotrexate disposition networks are associated with the deficit phenotype (TRANCE) of childhood leukemia survivors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors

NCT01014195

Neurocognitive Impairment Acute Lymphoblastic Leukemia

COMPLETED

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery

NCT02767388

Myelodysplastic Syndrome Effects of Chemotherapy Mild Cognitive Impairment +6 more

COMPLETED

Patient-Reported Outcome Version of the Common Criteria for Adverse Events

NCT04050072

Survivorship Cancer

ACTIVE_NOT_RECRUITING

Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study

NCT02309242

Sarcoma, Soft Tissue Osteosarcoma Tumor

UNKNOWN NA

Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer

NCT00260975

Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothesis Genetic variants of the elements in the folate-related cycles and methotrexate disposition networks are associated with the TRANCE phenotype of childhood leukemia survivors.

Objectives

1. To identify TRANCE phenotypes of the childhood leukemia survivors.
2. To characterize the folate and vitamin B12 levels of these children
3. To identify DNA methylation patterns associated with TRANCE trait in the leukemia survivors
4. To identify SNPs associated with the TRANCE trait in the leukemia survivors.
5. To identify the "deficit genotype" associated only with the TRANCE leukemia survivors, but not with general population children who show developmental phenotypes similar to TRANCE: TRANCE-unique deficit variant
6. To replicate the association between the TRANCE-unique deficit variants and the TRANCE trait in a population of childhood leukemia survivors.
7. To evaluate the importance of rare genetic variants in the TRANCE trait in the leukemia survivors.

Study design: A case-control study of leukemia survivors

Analyses

1. Leukemia survivors will be characterized by their status of neurocognitive function, and categorized into the Deficit case and the non-deficit Control case.
2. They will be also characterized by the following attributes

1. Pathway-based genetic variant status (folate and PK-related genes)
2. Folate and vitamin B12 status
3. Epigenetic markers
3. Comparative analyses between neuro-cognitiive deficit phenotype (TRANCE) and Control on those parameters

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Childhood Leukemia Survivors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Leukemia survivors with neurocognitive deficit

Leukemia survivors with neuro-cognitive deficit phenotype. Based on DIVERGET and other phenotyping tools, we will identify those with the deficit phenotype. This will be treated as "case".

No interventions assigned to this group

Leukemia survivors without neurocognitive deficit

Leukemia survivors who did not show impaired neurocognitive function, compared to the Control group defined above.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Past diagnosis of acute lymphoblastic leukemia
* 8 years : 0 months - 20 years : 11 months old at the time of their study visit
* At least 2 years : 0 months from the last treatment for acute lymphoblastic leukemia at the time of their study visit
* Continuous complete remission and undergone no bone marrow transplantation or cranial radiation therapy
* Fluent in English (a subject and one parent) for test completion
* Signed informed consent